Delayed malignant melanoma recurrence simulating primary ovarian cancer: Case report

Boutis, Anastasios; Valeri, R; Korantzis, Ioannis; Valoukas, Dimitrios; Andronikidis, Ioannis; Andreadis, Charalambos

doi:10.1186/1477-7819-6-124

Cited by 10 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For melanoma, no studies reporting on autotransplantation of ovarian tissue, or epidemiology of ovarian involvement were retrieved from the literature. However, numerous case reports were identified describing ovarian metastases from melanoma (Silveira et al, 1977;Gonzalez and Hammond, 1983;Martinelli et al, 1984;Fitzgibbons et al, 1987;Blumenfeld et al, 1991;Young and Scully, 1991;Murphy et al, 1994;Remadi et al, 1997;Moselhi et al, 1998;Nakano et al, 1998;Piura et al, 1998;Santeusanio et al, 2000;Gupta et al, 2004;Rey-Caballero et al, 2004;Belagyi et al, 2006;Jeremic et al, 2006;Bloch-Marcotte et al, 2008;Boutis et al, 2008;Milicevic et al, 2008;Shuhaila et al, 2008;Abe et al, 2009;Bahat et al, 2009;Fenzl et al, 2011;Sbitti et al, 2011;Habek et al, 2012). Apart from cases of ovarian metastases from cutaneous melanomas of different body locations, reports on choroidal melanomas metastasizing to the ovaries were published (Santeusanio et al, 2000;Rey-Caballero et al, 2004;Bloch-Marcotte et al, 2008).…”

Section: Melanoma and Malignant Blue Naevusmentioning

confidence: 99%

Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review

Bastings

Beerendonk

Westphal

et al. 2013

Human Reproduction Update

195

105

View full text Add to dashboard Cite

BACKGROUND The risk of recurrent oncological disease due to the reintroduction of cancer cells via autotransplantation of cryopreserved ovarian tissue is unknown. METHODS A systematic review of literature derived from MEDLINE, EMBASE and the Cochrane Library was conducted. Studies on follow-up after autotransplantation; detection of cancer cells in ovarian tissue from oncological patients by histology, polymerase chain reaction or xenotransplantation; and epidemiological data on ovarian metastases were included. RESULTS A total of 289 studies were included. Metastases were repeatedly detected in ovarian tissue obtained for cryopreservation purposes from patients with leukaemia, as well as in one patient with Ewing sarcoma. No metastases were detected in ovarian tissue from lymphoma and breast cancer patients who had their ovarian tissue cryopreserved. Clinical studies indicated that one should be concerned about autotransplantation safety in patients with colorectal, gastric and endometrial cancer. For patients with low-stage cervical carcinoma, clinical data were relatively reassuring, but studies focused on the detection of metastases were scarce. Oncological recurrence has been described in one survivor of cervical cancer and one survivor of breast cancer who had their ovarian tissue autotransplanted, although these recurrences may not be related to the transplantation. CONCLUSIONS It is advisable to refrain from ovarian tissue autotransplantation in survivors of leukaemia. With survivors of all other malignancies, current knowledge regarding the safety of autotransplantation should be discussed. The most reassuring data regarding autotransplantation safety were found for lymphoma patients.

show abstract

Section: Melanoma and Malignant Blue Naevusmentioning

confidence: 99%

Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review

Bastings

Beerendonk

Westphal

et al. 2013

Human Reproduction Update

195

105

View full text Add to dashboard Cite

show abstract

“…Two major case series of ovarian MM provided detailed insight to these rare cases [7,8]. Individual case reports were also found in the literature [6,[9][10][11][12][13]. Over 60% of these patients had known histories of cutaneous melanomas or pigmented lesions.…”

Section: Discussionmentioning

confidence: 99%

“…Surgery is a suitable approach for resectable tumors [2,11]. The role of postoperative chemotherapy is controversial but has been shown to be beneficial by some studies [9][10][11]. BRAF mutation is present in about 50% of metastatic MM of unknown primary tumors [24].…”

Section: Discussionmentioning

confidence: 99%

Melanoma of unknown primary origin metastasizing to the ovary and breast: Case report and review of literature

Niu¹,

L²,

Peng³

2019

J Mod Hum Pathol.

View full text Add to dashboard Cite

Malignant melanoma (MM) simultaneously involving the ovary and breast is a rare manifestation of the disease. We report a case of amelanotic MM of unknown primary origin manifesting as a large ovarian solid mass at its first clinical presentation. A 46-year-old woman presented with a two week history of lower abdominal pain. Imaging studies revealed an 18 cm right ovarian mass and a 1.1 cm left breast mass. The ovarian mass was first removed and it showed smooth capsule. Histologically, the tumor exhibited predominantly solid and nested growth patterns with scattered follicle-like spaces. The cells had large atypical nuclei with prominent nucleoli, and brisk mitotic activity. No melanin pigment was identified. No evidence of mature teratoma in the ovary was found. Immunohistochemically, the tumor was diffusely positive for SOX10, S-100, HMB-45, Melan-A and WT-1, and negative for cytokeratins, PAX-8, ER, PR, CD45, SALL4, and inhibin. Biopsy of the breast lesion showed a poorly differentiated malignancy with identical morphology. A diagnosis of metastatic melanoma to the ovary and breast was established. Thorough physical examination and imaging study revealed no evidence of cutaneous, uveal, or mucosal lesions. Probably, a primary MM was occult or had regressed. Subsequent molecular test for BRAF V600E mutation in the tumor was positive. The patient rapidly developed widespread metastasis. Immunotherapy was initiated; she had excellent response with significant tumor regression at her six month follow up visit. This case represents an example that making correct and timely diagnosis of metastatic melanoma followed by prompt targeted therapy significantly improved the patient's clinical outcome.

show abstract

“…In the nontransplant setting, malignant melanoma has been described to recur many years after initial 'curative' treatment [11][12][13][14][15][16][17]. Approximately 1-7% of melanomas have been reported to recur beyond 10 years, with one report of recurrence occurring after a 35-year disease-free interval [12,18].…”

Section: Discussionmentioning

confidence: 99%

Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection

Bajaj

Watt

Hadjiliadis

et al. 2010

Transplant International

View full text Add to dashboard Cite

Summary In the current era of organ shortages and long wait times for life‐saving transplants, marginal or extended donors are increasingly being considered; one such category of marginal organs is from donors with a previous history of malignancy. Melanoma in particular has been associated with increased risk of developing late recurrence. In this report, we describe a case of fatal donor melanoma transmission to a 64‐year‐old lung transplant recipient 32 years after surgical excision of the melanoma. Based on this report and review of the available literature, we conclude that a history of donor melanoma, regardless of the stage and time interval from ‘curative’ surgical resection, should remain a strong relative contraindication to transplantation.

show abstract

Delayed malignant melanoma recurrence simulating primary ovarian cancer: Case report

Cited by 10 publications

References 18 publications

Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review

Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review

Melanoma of unknown primary origin metastasizing to the ovary and breast: Case report and review of literature

Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection

Contact Info

Product

Resources

About